FDA Panel’s Surprising Vote on Peptides: What It Means for Patients and Providers
In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) shocked many observers by narrowly recommending six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for potential inclusion on the 503A…